Erasmus School of Health Policy & Management
External PhD candidate | Health Technology Assessment (HTA)
- j.walraven@eshpm.eur.nl
More information
Work
- Jelle Walraven, Mahtab Kaveh & Carin Uyl - de Groot (2026) - Methodological challenges in Dutch HTA of non-oncological orphan drugs: a retrospective analysis and price comparison using different pricing models - Orphanet Journal of Rare Diseases, 21 (1) - doi: 10.1186/s13023-025-04181-6 - [link]
- Jelle Walraven, Maartje S. Jacobs & Carin A. Uyl-de Groot (2022) - Author's Reply - Value in Health, 25 (6), 1058-1059 - doi: 10.1016/j.jval.2022.01.018 - [link]
- Jelle Walraven, Maartje S. Jacobs & Carin A. Uyl-de Groot (2021) - Leveraging the Similarities Between Cost-Effectiveness Analysis and Value-Based Healthcare - Value in Health, 24 (7), 1038-1044 - doi: 10.1016/j.jval.2021.01.010 - [link]
